Clinical trials
Metastatic Liver Cancer clinical trials
Below are recruiting metastatic liver cancer clinical trials, each written for real people, not researchers. We’re tracking 817 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07400354Recruiting
PD-1 drug plus chemo for advanced stomach cancer based on gut bacteria
This trial tests if adding a PD-1 immunotherapy drug to standard chemotherapy works better for advanced stomach cancer, and looks at how your gut bacteria may affect treatment. It is for people who have not had chemotherapy before and are starting their first treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07379268Recruiting
Anti-HER2 drug for advanced bladder cancer
This trial tests an antibody-drug conjugate that targets HER2 in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for patients whose cancer has not responded to or stopped responding to platinum-based chemotherapy.
Jinan, ShandongAges 18–80 - NCT07034053RecruitingPhase 1/Phase 2
Clofarabine for advanced bladder cancer
This trial tests the drug clofarabine in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for those who have already tried standard treatments or chose not to have them.
ViennaAges 18 years+ - NCT06609187RecruitingPhase 1
Study of GNC-077 for advanced breast cancer and other solid tumors
This trial tests a new drug called GNC-077 for people with advanced breast cancer or other solid tumors that have spread. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03990896RecruitingPhase 2
Talazoparib for metastatic breast cancer with BRCA body DNA changes
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
San Francisco, CaliforniaAges 18 years+ - NCT04585958RecruitingPhase 1
Combination treatment for HER2-positive cancers and resistant ovarian cancer
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06789848RecruitingPhase 2
Testing two immunotherapy drugs for advanced liver and bile duct cancers
This trial tests two investigational drugs, ligufalimab and cadonilimab, for people with advanced liver cancer (hepatocellular carcinoma, HCC) or bile duct cancer (biliary tract cancer, BTC) that has not responded to previous treatment with an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
Dallas, TexasAges 18 years+ - NCT05003895RecruitingPhase 1
CAR-T for solid tumors with high GPC3 protein
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Bethesda, MarylandAges 18–120 - NCT07441889RecruitingPhase 1/Phase 2
HER2-targeting immune cells for metastatic breast and prostate cancer
This trial tests a new treatment using specially designed immune cells that target HER2, a protein found on some cancer cells. It is for people with metastatic breast or prostate cancer that has worsened after prior treatments.
Charlottesville, VirginiaAges 18 years+ - NCT04329494RecruitingPhase 1
Study of targeted drug delivery into the abdomen using PIPAC
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
Duarte, CaliforniaAges 18 years+ - NCT06526299RecruitingPhase 2
Higher dose of targeted radiation for prostate cancer with low PSMA levels
This trial tests a higher dose of a radioactive drug (177Lu-PSMA-617) for men whose prostate cancer has spread and does not produce much of a protein called PSMA on scans. The goal is to see if a stronger dose can work better than the standard dose.
San Francisco, CaliforniaAges 18 years+ - NCT04468061RecruitingPhase 2
Study chemo drug plus immunotherapy for metastatic triple-negative breast cancer
This trial tests sacituzumab govitecan (an antibody-drug medicine) with or without pembrolizumab (an immune-system therapy) in people with metastatic triple-negative breast cancer. It may help by shrinking tumors and improving immune control, especially for patients with specific tumor marker results.
Stamford, ConnecticutAges 18 years+ - NCT05535413RecruitingPhase 1/Phase 2
UTD1 plus capecitabine for HER2-negative breast cancer brain mets
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
ChangshaAges 18–70 - NCT07333066RecruitingPhase 3
Adding chemotherapy when first treatment response is limited
This trial tests whether adding a chemotherapy drug (docetaxel) to your current treatment (apalutamide) can help control prostate cancer that has spread and hasn't responded as well as hoped to apalutamide alone.
BayonneAges 18 years+ - NCT06236269RecruitingPhase 2
Sacituzumab Govitecan for HR+/HER2- advanced breast cancer
This trial tests a drug called Sacituzumab Govitecan for people with HR+/HER2- advanced or metastatic breast cancer that has stopped responding to a CDK4/6 inhibitor. It looks at whether the drug can slow down the cancer and requires you to have a tumor biopsy.
Badalona, BarcelonaAges 18 years+ - NCT07452224RecruitingPhase 2
Combination treatment for advanced lung cancer
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06042894RecruitingPhase 2
Study of two drugs for advanced HER2-negative breast cancer
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04946370RecruitingPhase 1/Phase 2
Pembrolizumab plus prostate cancer drug, with or without radiation
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
Boston, MassachusettsAges 18 years+ - NCT04886986RecruitingPhase 1
Testing a targeted radiation pill for advanced prostate cancer
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
Brooklyn, New YorkAges 18–99 - NCT06329973RecruitingPhase 1/Phase 2
Fruquintinib, sintilimab, and chemo for stomach cancer
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Zhengzhou, HenanAges 18–75 - NCT05582538RecruitingPhase 2
Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Novara, NovaraAges 18 years+ - NCT07724223RecruitingPhase 2
Combination targeted therapy for advanced colorectal cancer
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07653893Recruiting
T-DXd for breast cancer that has spread to the brain
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04400695RecruitingPhase 3
Targeted drug for breast cancer with low HER2 levels
This trial tests a new drug that targets breast cancer cells with low levels of the HER2 protein. It may offer a new treatment option for patients whose cancer has spread and not responded well to previous therapies.
Beijing, Beijing MunicipalityAges 18–70
Hear when a new Metastatic Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic liver cancer?
- Yes. Clin2 currently lists 817 recruiting metastatic liver cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic liver cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic liver cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.